Chemo-Induced Ovarian Failure in Young Women with Breast Cancer
the Cancer Therapy Advisor take:
Ovarian toxicity may derive from acute vascular insult caused by chemotherapy in patients with breast cancer, according to an article published online in the journal The Oncologist.
Participants in this study included 20 patients (median age of 34 ± 5.24 years) diagnosed with localized breast cancer. Transvaginal ultrasound was used to evaluate the patients prior to initiation of chemotherapy, immediately following treatment completion, and at 6 and 12 months post-treatment.
Using resistance index and pulsatility index, the authors concluded that ovarian blood flow was significantly reduced immediately following chemotherapy treatment (P=0.01). Patients younger than 35 years significantly regained ovarian vasculature after 6 and 12 months post-treatment, compared with patients older than 35 years (P<0.05).
Furthermore, all patients experienced a significant drop in anti-Müllerian hormone (AMH) levels following treatment (P=0.04). At 12 months, 50% of patients resumed menses.
Results indicated that chemotherapy-induced ovarian toxicity may result from acute vascular insult caused by treatment.
The authors noted that ovarian vasculature impairment was diminished in patients who underwent a trastuzumab-based treatment, although results were not statistically significant (P=0.068).
The study suggests future research work to further understand and characterize patterns of chemotherapy-induced vascular toxicity for specific organs.
Ovarian toxicity may derive from acute vascular insult caused by chemotherapy in patients with breast cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Ginkgo Biloba and Cancer
- Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use
- HIV-associated Head and Neck Cancers Have Unique Molecular Characteristics
- Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC
- Cost, Insurance Status May Affect Patient Adherence to TKI Therapy for CML
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured